BIOLQ Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 14185.71%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 136.11%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Biolase has a beta of 0.211, which suggesting that the stock is 78.874% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.429%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 7.95x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 0.18%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -32.33%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 14185.71%. On the other hand Envista Holdings has an analysts' consensus of $20.50 which suggests that it could grow by 32.6%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

Biolase has a beta of 0.211, which suggesting that the stock is 78.874% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.120, suggesting its more volatile than the S&P 500 by 12.044%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $1.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 1.06x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of -13.16% compared to Biolase's net margin of 1.49%. Biolase's return on equity of -21668.17% beat Solventum's return on equity of 9.76%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 14185.71%. On the other hand Solventum has an analysts' consensus of $80.89 which suggests that it could grow by 22.21%. Given that Biolase has higher upside potential than Solventum, analysts believe Biolase is more attractive than Solventum.

Biolase has a beta of 0.211, which suggesting that the stock is 78.874% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Solventum quarterly revenues of $2.1B. Biolase's net income of -$1.4M is lower than Solventum's net income of $31M. Notably, Biolase's price-to-earnings ratio is -- while Solventum's PE ratio is 24.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 1.39x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -47.51%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -32.39%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 14185.71%. On the other hand Dentsply Sirona has an analysts' consensus of $19.18 which suggests that it could grow by 50.19%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

Biolase has a beta of 0.211, which suggesting that the stock is 78.874% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.918, suggesting its less volatile than the S&P 500 by 8.232%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 5.01% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $905M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$430M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 0.69x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.